摘要
The receptor tyrosine kinase c-Met is an attractive target for therapeutic treatment of cancers nowadays. The discovery of small molecule inhibitors is of special interest in the blockade of the c-Met kinase pathway. Here, we initiated our study from compound 1a, a novel inhibitor against c-Met kinase. A substructure similarity search against the SPECS database and chemical synthesis methods were performed to obtain a series of pyrazolidine-3,5-dione derivatives. Through the enzyme-based assay against c-Met kinase, 4 compounds (1c, 1e, 1m and 1o) showed potential inhibitory activity, with IC50 values mostly less than 10 mu M. Based on the structure-activity relationship (SAR) and binding mode analysis, a focused combinatorial library was designed by the LD1.0 program. Taking into account ADMET properties and synthesis accessibility, seven candidate compounds (5a-g) were successfully synthesized. The activity of the most potent compounds 5b (IC50 = 0.46 mu M) was 20 fold higher than that of the lead 1a. Taken together, our findings identified the pyrazolidine-3,5-dione derivatives as potent inhibitors against c-Met kinase and demonstrated the efficiency of the strategy in the development of small molecules against c-Met kinase.
- Design and Synthesis of Some Novel 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as Potential c-Met InhibitorsYe Lianbao; Tian Yuanxin; Li Zhonghuang; Zhang Jiajie*; Wu ShuguangHelvetica Chimica Acta, 2012, 95(2): 320-326.被引 7
- Identification and synthesis of N '-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinaseLiang Zhongjie; Zhang Dengyou; Ai Jing; Chen Limin; Wang Hengshuai; Kong Xiangqian; Zheng Mingyue; Liu Hong*; Luo Cheng; Geng Meiyu; Jiang Hualiang; Chen KaixianBioorganic and Medicinal Chemistry Letters, 2011, 21(12): 3749-3754.被引 15
- Biological activity, Molecular Docking Studies and Molecular Dynamics Simulations of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b] indoles as c-Met inhibitorsYe Lianbao*; Wu Jie; Yang Jiebo; Chen Weiqiang; Luo Yan; Zhang YanmeiLATIN AMERICAN JOURNAL OF PHARMACY, 2016, 35(2): 416-420.
